ScholarIQanswers from OpenAlex & ORCID
Steven M. Haffner
ResearcherPublications, citations & collaboration network
Steven M. Haffner is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Steven M. Haffner have?
ScholarIQindexed works
Steven M. Haffner has 599 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Steven M. Haffner have?
ScholarIQcitation count
Steven M. Haffner has 90,058 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Steven M. Haffner?
ScholarIQh-index
Steven M. Haffner has an h-index of 141 in OpenAlex.
What is the i10-index of Steven M. Haffner?
ScholarIQi10-index
Steven M. Haffner has an i10-index of 510 in OpenAlex.
What is the OpenAlex record for Steven M. Haffner?
ScholarIQopenalex
The OpenAlex for Steven M. Haffner is on the source record.
What are the most-cited papers on Steven M. Haffner?
ScholarIQmost cited works
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Steven E. Kahn, Steven M. Haffner, Mark Heise, William H. Herman, Rury R. Holman, Nigel C. Jones, Barbara G. Kravitz, John M. Lachin, Mark O’Neill, Bernard Zinman, Giancarlo Viberti
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Deepak L. Bhatt, Keith A.A. Fox, Werner Hacke, Peter B. Berger, Henry R. Black, William E. Boden, P. Cacoub, Eric A. Cohen, Mark A. Creager, J. Donald Easton, Marcus Flather, Steven M. Haffner, Christian W. Hamm, Graeme J. Hankey, S. Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A. Pearson, Philippe Gabríel Steg, Steven R. Steinhubl, Michael A. Weber, Danielle M. Brennan, Liz Fabry-Ribaudo, Joan E. Booth, Eric J. Topol
Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study
Naveed Sattar, Allan Gaw, Olga Scherbakova, Ian Ford, D S O’Reilly, Steven M. Haffner, Chris Isles, Peter W. Macfarlane, Chris J. Packard, Stuart M. Cobbe, James Shepherd
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans‐Henrik Parving, Barry M. Brenner, John J.V. McMurray, Dick de Zeeuw, Steven M. Haffner, Scott D. Solomon, Nish Chaturvedi, Frederik Persson, Akshay S. Desai, Maria Nicolaides, Alexia Richard, Zhihua Xiang, Patrick Brunel, Marc A. Pfeffer